Share Name Share Symbol Market Type Share ISIN Share Description
Spire Health LSE:SPI London Ordinary Share GB00BNLPYF73 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +4.40p +2.83% 159.90p 3,499,706 16:35:16
Bid Price Offer Price High Price Low Price Open Price
159.50p 159.70p 163.50p 150.60p 154.10p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 931.70 22.70 4.20 38.1 641.3

Spire Health (SPI) Latest News (2)

More Spire Health News
Spire Health Takeover Rumours

Spire Health (SPI) Share Charts

1 Year Spire Health Chart

1 Year Spire Health Chart

1 Month Spire Health Chart

1 Month Spire Health Chart

Intraday Spire Health Chart

Intraday Spire Health Chart

Spire Health (SPI) Discussions and Chat

Spire Health Forums and Chat

Date Time Title Posts
21/9/201814:40Spire Health727
15/1/201713:48Spice Holdings PLC1,547
07/10/201102:44Stanard and Very Poor-
31/1/201018:33Man, a spiritual being or an animal?192
12/8/200011:36Spirent PLC-

Add a New Thread

Spire Health (SPI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Spire Health trades in real-time

Spire Health (SPI) Top Chat Posts

Spire Health Daily Update: Spire Health is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SPI. The last closing price for Spire Health was 155.50p.
Spire Health has a 4 week average price of 148.60p and a 12 week average price of 148.60p.
The 1 year high share price is 307p while the 1 year low share price is currently 148.60p.
There are currently 401,081,391 shares in issue and the average daily traded volume is 4,524,822 shares. The market capitalisation of Spire Health is £641,329,144.21.
eastbourne1982: The update was pretty much in line, why the share price dropped 12% at one point is beyond me.
analyst: Private healthcare operator NMC Health revealed a strong set of half year results and a raft of new acquisitions, giving the share price a 4.6% boost to £42.46.
jonwig: In the meantime, we downgrade our 2018 EBITDA by 16% and EPS by 37%, noting that this implies gearing of 3.7x EBITDA at the end of 2018 (covenant 4.0x). With the shares down by 20% since our upgrade, our waning confidence in our prior investment thesis prompts us to consider a stop-loss action. Our new valuation, based on EV/EBITDA and DCF metrics that reflect higher risk, leads to a 120p/share price target. We therefore set our recommendation to Sell, and believe there is potential for intangible asset write-downs and a dividend cut. Speculation regarding the potential for Mediclinic to acquire Spire helps to the limit downside, but Mediclinic’s five-year low share price, and the negative reaction to its previous bid for Spire, adds risk to relying on that get-out-of-jail-free card.
bolador: I read that there are significant directors holdings in this stock. Seeing as how a few months ago they thought the shares worth buying at around 200p perhaps they might think it worthwhile to take the company private ? The share price carnage must be far worse than they were expecting on the profits warning.
cantrememberthis2: E1982 = Very attractive share price for many non Private Investors IMO MDC Offered 315p Share Price 155p on print NHS is the NHS and skint So the news was no suprise People get ill, die etc... Its not a widow/orphans stock but man this is cheap.
eastbourne1982: NMC has a very strong share price at the moment and a market cap of over 8 billion, I wonder if they could be tempted by SPI. A combined share and cash deal for SPI could be relative peanuts for them and good timing.
bolador: It seems to me that take over offers and bids should be a matter of shareholder votes. So often bids are rejected and disaster follows. Perhaps it is too much to expect directors to vote themselves out of office. This share price is now nearly half of the recent rejected bid value.You would have thought the bid too good a chance to miss, well ,you would if you had any idea how the business was going ! The board should glow with embarrassment but I doubt they will.
bountyhunter: fair points EI, any bidder would have to be thinking medium to long term and making cost savings including from business synergies, but if the price was right now may be a good time for a predator while all is doom and gloom and the share price is way down (and self paying patients are actually on the rise - "In H1 2018, Self-Pay revenues increased 8.3%")
che7win: Yes bounty, MDC might be barred from takeover for 6months, not sure, or unless someone else comes in with an offer.But nothing to stop others taking this over, plenty of US companies could use a weak exchange rate in their favour, never mind a weak SPI share price to offer 350p a share.Who knows, the chart has broken out from the low point though, would be nice to get to 300p from here short term.
tonysss13: Mediclinic said to weigh £1.8 billion plus takeover bid for Spire Healthcare Friday, 16 September 2016, 11:03 am Mediclinic is preparing to bid for Spire Healthcare, the FTSE 250 company that was formed from the sale of BUPA hospitals. According to excellent sources, Mediclinic is working with bankers from Morgan Stanley on the potential purchase of the remainder of Spire Healthcare that it doesn't own (remember last year Mediclinic bought 29.9pc of Spire Healthcare for 360p a share). Now, to be clear I'm not the first financial journalist to raise the prospect of a Mediclinic bid for Spire Healthcare. In late August, several British stock market reporters picked up on a note from JP Morgan, which theorised that now might be the right time for FTSE 100-listed Mediclinic to buy the remainder of Spire given the currency fluctuations post the Brexit referendum. I have pasted the relevant paragraphs from the JP Morgan note below: "In our view, the weakness in the GBP and strength of MDC’s share price vs Spire’s is an opportunity for MDC to consolidate its ownership of Spire (currently 29.9%). We estimate it could pay a 35% premium for Spire and see year one EPS increase by 3-4%, rising to 10% in year three assuming a debt-based deal. Alternatively, if MDC chose to raise equity ~£300m-500m (4-7%) in order to leave less gearing and also fund Spire’s London hospital expansion, year one accretion would drop to 2-1%. We note the authority to raise equity afforded Remgro, MDC’s largest shareholder (~44.6%), at its Aug-16th AGM." But from what I understand from excellent sources is bankers from Morgan Stanley, Mediclinic's financial advisers, are actually working on the deal suggested by the JP Morgan analyst. One source reckons Mediclinic is just a few weeks away from submitting a formal approach for Spire. I don't have much more information than that but I have been told any offer is likely to be at about a 30pc premium to the current share price. Mediclinic declined to comment. However, people familiar with the company tried to play down the tale, unsurprisingly. - See more at: hxxp://
Spire Health share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180924 01:21:18